A MUC1-C–specific HLA-A24+ T-cell line derived from a patient with prostate cancer was stimulated using its specific MUC1 peptide and DCs treated with 0, 0.25 or 1.0 μM of epacadostat. Here, MUC1 is linked to prostate carcinoma.